DEVELOPING BREAKTHROUGH THERAPIES THAT HARNESS THE BODY’S OWN REGENERATIVE CAPACITY
Founded in 2011, Recardio is a clinical stage life sciences company headquartered in San Francisco, California. Our multinational management team and our scientific and clinical advisors are based in the US and in Europe.
The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating the chemokine SDF-1, a protein that is critical in guiding stem cell migration to the injured heart for repair and regeneration. In addition to its current Phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. In addition other development programs in oncology and infectious diseases are in preclinical stage.